MUMBAI,
India /PRNewswire/ -- Pharma Major Lupin Limited
(Lupin) today announced that it has entered into a strategic asset
purchase agreement with TEMMLER PHARMA GMBH & CO. KG (Temmler),
a part of the Aenova Group, one of the world's largest
pharmaceutical contract manufacturers, to acquire Temmler's
specialty product portfolio subject to certain closing
conditions.
Based in Marburg
(Germany),
Temmler has a fast growing specialty portfolio of 13 products
including key Central Nervous System (CNS) products and specialty
products that address rare disease areas like Myasthenia Gravis,
Huntington disease as well as fast-growing dermatology products for
anti-wart treatment. Since Huntington disease has many symptoms
ranging from motoric symptoms to personality changes, both Temmler
and Hormosan products can be used to treat the disease.
Commenting on the
acquisition, Ms. Vinita Gupta, Chief Executive Officer of
Lupin Limited said, "We are very pleased to add to our specialty
business with this acquisition. Temmler's business has a
strong strategic fit with Lupin's Hormosan business
in Germany and
enables Lupin to bring an enhanced specialty CNS portfolio to the
German market."
Dr. Maurice
Chagnaud, President - Europe and Head of Inhalation Strategy,
commented, "Temmler is a profitable pharmaceutical player backed by
a strong and experienced management team that is also taken on and
which will strongly support our future growth plans. Temmler
operates in niche segments and its specialty product portfolio has
strong synergies with Hormosan's existing CNS portfolio. The
acquisition not only complements but would also enhance Hormosan's
specialty portfolio and enables it to grow into niche therapy
areas.
Mr. Frank
Elsen, Aenova Group CFO commented, "I believe that Lupin is
perfectly poised to take Temmler's product portfolio and its growth
forward. We are extremely optimistic about this strategic agreement
which allows us to concentrate on our core business. As a leading
CDMO we are proud to continue to manufacture and supply at highest
quality all related products to our partner Lupin."
About Lupin
Limited
Headquartered
in Mumbai,
Lupin is an innovation led transnational pharmaceutical company
producing and developing a wide range of branded & generic
formulations, APIs and biotechnology products. The Company is a
significant player in the Cardiovascular, Diabetology, Asthma,
Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global
leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the
5th largest
and fastest growing generics player in the US (5.3% market share by
prescriptions, IMS Health) and the 3rd largest
Indian pharmaceutical company by sales. The Company is also the
fastest growing top 10 generic pharmaceutical players
in Japan and South
Africa (IMS).
For the financial
year ended 31st March
2015, Lupin's Consolidated turnover and Profit after Tax
were Rs. 125,997 million (USD
2.06 billion) and Rs. 24,032 million (USD
393 million) respectively. Please visithttp://www.lupin.com for more
information.
About Aenova Group
The Aenova Group
is one of the world's largest providers of services covering the
entire value chain for the development and production of all the
main dosage forms and product groups in the field of medicines and
dietary supplements. As the European business-to-business market
leader, the Aenova Group focuses on high standards of quality,
innovative technologies and a clear vision for the future. The
group operates overall 29 locations in eleven countries and employs
more than 4700 people.
You could also
follow us on Twitter - http://www.twitter.com/lupinlimited
CIN: L24100MH1983PLC029442
Registered Office: 159,
C.S.T. Road, Kalina, Santacruz
(East), Mumbai -
400 098.
For further
information or queries please contact -
Shamsher
Gorawara
Head - Corporate Communications
Lupin Limited:
Ph: +91-98-20-338-555
Email: [email protected]
Safe Harbor
Statement